8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Dec 8, 2025·SEC
Arcellx, Inc.(ACLX)Earnings, Financials & Key Ratios
ACLX•NASDAQ
$115.07
Price updated Jun 20, 2026
AboutArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.Show more
- Revenue$22M-79.4%
- EBITDA-$246M-86.1%
- Net Income-$229M-113.3%
- EPS (Diluted)-4.07-103.5%
- Gross Margin70.03%-26.4%
- EBITDA Margin-1105.65%-801.5%
- Operating Margin-1135.61%-791.0%
- Net Margin-1027.25%-932.9%
- ROE-53.42%-133.9%
ACLX Price & Volume
Arcellx, Inc. (ACLX) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependence Masks Structural Clinical Cash Burn
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone liquidity dependency
Key Thesis Takeaways
- Arcellx faces a challenging outlook characterized by extreme revenue volatility, as evidenced by a 89.2% year-over-year revenue contraction in 2025Q4 due to its reliance on non-recurring milestone payments.
- The company's heavy R&D intensity, consistently exceeding $34 million per quarter, continues to drive significant operating losses and erodes the equity base, which has fallen to $402.4 million.
- Investors should monitor the company's ability to secure further capital, as the rapid depletion of cash reserves to $80.3 million necessitates a transition toward sustainable commercialization or further dilutive financing.
Verdict Logic
the company's liquidity is rapidly eroding, evidenced by a cash position that has plummeted from $394.6 million in 2023Q4 to just $80.3 million in 2025Q4.
ACLX Growth Metrics
Arcellx, Inc. (ACLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-79.35%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-113.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-101.99%
Return on Capital
10 Years-57.76%
5 Years-53.56%
3 Years-28.85%
Last Year-46.62%
ACLX Recent Earnings
Arcellx, Inc. (ACLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q1 2026Latest
Feb 26, 2026Metric
Actual
Est
EPS
$1.01+0.0%
$1.01
Rev
$4M-65.0%
$13M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.99-3.1%
$0.96
Rev
$5M-60.9%
$13M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.94+8.7%
$1.03
Rev
$8M-44.9%
$14M
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$1.13-34.5%
$0.84
Rev
$8M-36.8%
$13M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $1.01vs $1.01+0.0% | $4Mvs $13M-65.0% |
| Q4 2025 | Nov 5, 2025 | $0.99vs $0.96-3.1% | $5Mvs $13M-60.9% |
| Q3 2025 | Aug 7, 2025 | $0.94vs $1.03+8.7% | $8Mvs $14M-44.9% |
| Q2 2025 | May 8, 2025 | $1.13vs $0.84-34.5% | $8Mvs $13M-36.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Arcellx, Inc. (ACLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -53.42% | — | |
| $27.68 | $5.12B | -17.30 | 64.04% | -21.97% | -24.91% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $2.15 | $524.32M | -2.47 | -100% | — | -56.45% | — |
Compare ACLX vs Peers
Arcellx, Inc. (ACLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACLX SEC Filings & Documents
Arcellx, Inc. (ACLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ACLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACLX Frequently Asked Questions
Arcellx, Inc. (ACLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Arcellx, Inc.'s revenue?
Arcellx, Inc. (ACLX) reported $22.3M in revenue for fiscal year 2025.
How fast is Arcellx, Inc. growing?
Arcellx, Inc. (ACLX) saw revenue decline by 79.4% over the past year.
Is ACLX profitable?
Arcellx, Inc. (ACLX) reported a net loss of $228.9M for fiscal year 2025.
Dividend & Returns
What is ACLX's return on equity?
Arcellx, Inc. (ACLX) has a return on equity (ROE) of -53.4%. Negative ROE indicates the company is unprofitable.
What is Arcellx, Inc.'s free cash flow?
Arcellx, Inc. (ACLX) had negative free cash flow of $212.6M in fiscal year 2025, likely due to heavy capital investments.